MX2021013110A - Compuestos heterociclicos como inhibidores de la cinasa ret. - Google Patents
Compuestos heterociclicos como inhibidores de la cinasa ret.Info
- Publication number
- MX2021013110A MX2021013110A MX2021013110A MX2021013110A MX2021013110A MX 2021013110 A MX2021013110 A MX 2021013110A MX 2021013110 A MX2021013110 A MX 2021013110A MX 2021013110 A MX2021013110 A MX 2021013110A MX 2021013110 A MX2021013110 A MX 2021013110A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- kinase inhibitors
- ret kinase
- heterocyclic compounds
- ret
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000001890 transfection Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La presente invención se refiere a compuestos de Fórmula I que funcionan como inhibidores de la actividad de encima cinasa de RET (reorganizado durante la transfección): (ver Fórmula) Fórmula I en donde HET, los enlaces a, b, c y d, X1, X2, X3, X4, R2 y R3 son cada uno como se definen en la presente. La presente invención también se refiere a procesos para la preparación de estos compuestos, a composiciones farmacéuticas que los comprenden, y a su uso en el tratamiento de trastornos proliferativos, tales como el cáncer, así como otras enfermedades o afecciones en las que está involucrada la actividad de cinasa de RET.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606631 | 2016-04-15 | ||
| GB201619277 | 2016-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013110A true MX2021013110A (es) | 2021-11-17 |
Family
ID=58633035
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012609A MX2018012609A (es) | 2016-04-15 | 2017-04-18 | Compuestos heterociclicos como inhibidores de la cinasa ret. |
| MX2021013110A MX2021013110A (es) | 2016-04-15 | 2018-10-15 | Compuestos heterociclicos como inhibidores de la cinasa ret. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012609A MX2018012609A (es) | 2016-04-15 | 2017-04-18 | Compuestos heterociclicos como inhibidores de la cinasa ret. |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10954241B2 (es) |
| EP (2) | EP3960180A1 (es) |
| JP (3) | JP6943876B2 (es) |
| KR (2) | KR102390578B1 (es) |
| CN (2) | CN115650985A (es) |
| AU (3) | AU2017250448C1 (es) |
| BR (2) | BR122023026297A2 (es) |
| CA (1) | CA3020778A1 (es) |
| CY (1) | CY1124478T1 (es) |
| DK (1) | DK3442980T3 (es) |
| ES (1) | ES2886587T3 (es) |
| HR (1) | HRP20211362T1 (es) |
| HU (1) | HUE056135T2 (es) |
| IL (3) | IL289793B2 (es) |
| LT (1) | LT3442980T (es) |
| MX (2) | MX2018012609A (es) |
| PL (1) | PL3442980T3 (es) |
| PT (1) | PT3442980T (es) |
| RS (1) | RS62322B1 (es) |
| RU (1) | RU2742115C2 (es) |
| SG (2) | SG10201911665UA (es) |
| SI (1) | SI3442980T1 (es) |
| WO (1) | WO2017178844A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20170098A (es) | 2010-05-20 | 2017-07-17 | Array Biopharma Inc | Compuestos macrociclicos como inhibidores de quinasa trk |
| MX2018000577A (es) | 2015-07-16 | 2018-09-05 | Array Biopharma Inc | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa. |
| HRP20231681T1 (hr) | 2015-11-02 | 2024-04-12 | Blueprint Medicines Corporation | Inhibitori za ret |
| DK3442535T3 (da) * | 2016-04-15 | 2022-09-05 | Cancer Research Tech Ltd | Heterocykliske stoffer som as ret-kinase-hæmmere |
| KR102390578B1 (ko) | 2016-04-15 | 2022-04-26 | 캔써 리서치 테크놀로지 리미티드 | Ret 키나아제 억제제로서의 헤테로사이클릭 화합물 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| EP3571203B1 (en) | 2017-01-18 | 2023-06-07 | Array BioPharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
| JP7061195B2 (ja) * | 2018-01-18 | 2022-04-27 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［３，４－ｄ］ピリミジン化合物 |
| US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
| MX2020010417A (es) | 2018-04-03 | 2021-01-08 | Blueprint Medicines Corp | Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret. |
| AU2019249721A1 (en) * | 2018-04-05 | 2020-09-17 | Merck Patent Gmbh | Heteroaryl compounds as type II IRAK inhibitors and uses hereof |
| WO2020055672A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| EP4364798A2 (en) | 2018-10-05 | 2024-05-08 | Annapurna Bio Inc. | Compounds and compositions for treating conditions associated with apj receptor activity |
| EP3950685A4 (en) * | 2019-04-03 | 2022-12-14 | Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory | PYRAZOLOPYRIDINE COMPOUND USED AS RET INHIBITOR AND USES THEREOF |
| JP7461605B2 (ja) * | 2020-02-20 | 2024-04-04 | 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 | キノリン系化合物 |
| CN113214294A (zh) * | 2020-06-10 | 2021-08-06 | 深圳铂立健医药有限公司 | 三环化合物、药物组合物及其应用 |
| WO2022076975A1 (en) | 2020-10-05 | 2022-04-14 | Enliven Therapeutics, Inc. | 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases |
| TW202241419A (zh) * | 2020-12-22 | 2022-11-01 | 美商基利科學股份有限公司 | ６－取代之吲哚化合物 |
| US20240059673A1 (en) * | 2020-12-22 | 2024-02-22 | Gilead Sciences, Inc. | Substituted indole compounds |
| AU2022257039A1 (en) | 2021-04-16 | 2023-10-05 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| CN113248518B (zh) * | 2021-06-21 | 2022-03-25 | 山东大学 | 嘧啶哌嗪类衍生物及其制备方法与应用 |
| WO2023064843A1 (en) | 2021-10-15 | 2023-04-20 | Stemline Therapeutics, Inc. | Inhibitors of mutant ret kinases for use in treating cancer |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0322779A3 (en) | 1987-12-29 | 1991-05-08 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzolactam compounds and pharmaceutical uses thereof |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| DE1140938T1 (de) * | 1999-01-11 | 2003-01-09 | Princeton University Princeton | Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7429596B2 (en) | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
| US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
| US9271963B2 (en) | 2005-03-03 | 2016-03-01 | Universitat Des Saarlandes | Selective inhibitors of human corticosteroid synthases |
| PT1951724E (pt) | 2005-11-17 | 2011-08-02 | Osi Pharm Inc | Inibidores mtor fundidos bicíclicos |
| AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
| JP5512975B2 (ja) | 2005-12-29 | 2014-06-04 | アッヴィ・インコーポレイテッド | タンパク質キナーゼ阻害薬 |
| GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
| JP2008063278A (ja) | 2006-09-07 | 2008-03-21 | Fujifilm Finechemicals Co Ltd | １−ピリジン−４−イル−インドール類の製造方法 |
| KR101315610B1 (ko) | 2006-09-22 | 2013-10-10 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
| US20090274698A1 (en) * | 2007-07-06 | 2009-11-05 | Shripad Bhagwat | Combination anti-cancer therapy |
| MX2010007418A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| WO2010006072A2 (en) | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
| JP5788316B2 (ja) | 2008-07-08 | 2015-09-30 | インテリカイン， エルエルシー | キナーゼインヒビターおよび使用方法 |
| JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン， エルエルシー | 複素環キナーゼ阻害剤 |
| US20110269779A1 (en) | 2008-11-18 | 2011-11-03 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
| KR101061599B1 (ko) * | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| MX352661B (es) | 2009-11-05 | 2017-12-04 | Rhizen Pharmaceuticals S A Star | Moduladores novedosos de benzopiran cinasa. |
| EP2528919B1 (en) | 2010-01-28 | 2016-11-02 | University of Washington | Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases |
| US9765037B2 (en) | 2010-01-28 | 2017-09-19 | University Of Washington Through Its Center For Commercialization | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| US20130296316A1 (en) | 2010-07-09 | 2013-11-07 | Michael P. Pollastri | Antiparasitic Agents Based On mTOR Inhibitors |
| AR085397A1 (es) | 2011-02-23 | 2013-09-25 | Intellikine Inc | Combinacion de inhibidores de quinasa y sus usos |
| CN103703174B (zh) | 2011-05-04 | 2017-05-10 | 因特利凯有限责任公司 | 联合药物组合物及其用途 |
| US9358229B2 (en) | 2011-08-10 | 2016-06-07 | Novartis Pharma Ag | JAK PI3K/mTOR combination therapy |
| JP6342805B2 (ja) * | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途 |
| WO2013070976A1 (en) | 2011-11-08 | 2013-05-16 | Intellikine, Llc | Treatment regimens using multiple pharmaceutical agents |
| EP2793893A4 (en) | 2011-11-23 | 2015-07-08 | Intellikine Llc | IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| US9738610B2 (en) | 2012-09-24 | 2017-08-22 | Whitehead Institute For Biomedical Research | Indazole derivatives and uses thereof |
| GB201217285D0 (en) | 2012-09-27 | 2012-11-14 | Univ Central Lancashire | Indole derivatives |
| JP2016512835A (ja) | 2013-03-15 | 2016-05-09 | インテリカイン， エルエルシー | キナーゼ阻害剤の組み合わせ及びそれらの使用 |
| CN105209042B (zh) | 2013-03-22 | 2019-03-08 | 米伦纽姆医药公司 | 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合 |
| US20160272645A1 (en) | 2013-10-18 | 2016-09-22 | Medivation Technologies, Inc. | Heterocyclic Compounds and Methods of Use |
| WO2015058084A1 (en) | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
| GB201321146D0 (en) | 2013-11-29 | 2014-01-15 | Cancer Rec Tech Ltd | Quinazoline compounds |
| ES2792036T3 (es) * | 2014-11-14 | 2020-11-06 | Nerviano Medical Sciences Srl | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de cinasa |
| CA2974702C (en) | 2015-01-26 | 2023-10-10 | University Of Washington | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases |
| US10550124B2 (en) | 2015-08-13 | 2020-02-04 | San Diego State University Foundation | Atropisomerism for increased kinase inhibitor selectivity |
| WO2017160717A2 (en) | 2016-03-15 | 2017-09-21 | Memorial Sloan Kettering Cancer Center | Method of treating diseases using kinase modulators |
| KR102390578B1 (ko) | 2016-04-15 | 2022-04-26 | 캔써 리서치 테크놀로지 리미티드 | Ret 키나아제 억제제로서의 헤테로사이클릭 화합물 |
| DK3442535T3 (da) * | 2016-04-15 | 2022-09-05 | Cancer Research Tech Ltd | Heterocykliske stoffer som as ret-kinase-hæmmere |
-
2017
- 2017-04-18 KR KR1020187032842A patent/KR102390578B1/ko active IP Right Grant
- 2017-04-18 BR BR122023026297-2A patent/BR122023026297A2/pt unknown
- 2017-04-18 BR BR112018071097-0A patent/BR112018071097B1/pt active IP Right Grant
- 2017-04-18 EP EP21172597.3A patent/EP3960180A1/en active Pending
- 2017-04-18 WO PCT/GB2017/051076 patent/WO2017178844A1/en active Application Filing
- 2017-04-18 MX MX2018012609A patent/MX2018012609A/es unknown
- 2017-04-18 DK DK17719687.0T patent/DK3442980T3/da active
- 2017-04-18 SG SG10201911665UA patent/SG10201911665UA/en unknown
- 2017-04-18 RS RS20211115A patent/RS62322B1/sr unknown
- 2017-04-18 JP JP2018554114A patent/JP6943876B2/ja active Active
- 2017-04-18 PL PL17719687T patent/PL3442980T3/pl unknown
- 2017-04-18 CN CN202211269931.2A patent/CN115650985A/zh active Pending
- 2017-04-18 CA CA3020778A patent/CA3020778A1/en active Pending
- 2017-04-18 US US16/093,854 patent/US10954241B2/en active Active
- 2017-04-18 PT PT177196870T patent/PT3442980T/pt unknown
- 2017-04-18 SG SG11201808878UA patent/SG11201808878UA/en unknown
- 2017-04-18 KR KR1020227013172A patent/KR20220054894A/ko not_active Application Discontinuation
- 2017-04-18 EP EP17719687.0A patent/EP3442980B1/en active Active
- 2017-04-18 LT LTEPPCT/GB2017/051076T patent/LT3442980T/lt unknown
- 2017-04-18 AU AU2017250448A patent/AU2017250448C1/en active Active
- 2017-04-18 SI SI201730892T patent/SI3442980T1/sl unknown
- 2017-04-18 HU HUE17719687A patent/HUE056135T2/hu unknown
- 2017-04-18 RU RU2018138471A patent/RU2742115C2/ru active
- 2017-04-18 ES ES17719687T patent/ES2886587T3/es active Active
- 2017-04-18 CN CN201780031509.4A patent/CN109195972B/zh active Active
- 2017-04-18 IL IL289793A patent/IL289793B2/en unknown
- 2017-04-18 IL IL297192A patent/IL297192A/en unknown
-
2018
- 2018-10-07 IL IL262185A patent/IL262185B/en unknown
- 2018-10-15 MX MX2021013110A patent/MX2021013110A/es unknown
-
2020
- 2020-08-18 AU AU2020220079A patent/AU2020220079B2/en active Active
-
2021
- 2021-02-02 US US17/165,151 patent/US11548896B2/en active Active
- 2021-08-26 HR HRP20211362TT patent/HRP20211362T1/hr unknown
- 2021-09-06 CY CY20211100784T patent/CY1124478T1/el unknown
- 2021-09-07 JP JP2021145468A patent/JP2021193108A/ja active Pending
-
2022
- 2022-06-06 AU AU2022203916A patent/AU2022203916A1/en active Pending
- 2022-11-22 US US17/992,049 patent/US20230339954A1/en active Pending
-
2023
- 2023-08-10 JP JP2023131211A patent/JP2023159230A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013110A (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
| EP4104837A3 (en) | Heterocyclic compounds as ret kinase inhibitors | |
| PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
| MX2017006366A (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa. | |
| PH12017502407A1 (en) | Fused pyrimidine compound or salt thereof | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| EA033343B1 (ru) | Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| AU2024202525A1 (en) | Benzimidazolone derived inhibitors of BCL6 | |
| PH12017500416A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| MX2015008957A (es) | Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1). | |
| EP2576549A4 (en) | Bicyclic Heteroarylkinase Inhibitors and Methods of Use | |
| MX2022006700A (es) | Compuestos poliheterociclicos como inhibidores de mettl3. | |
| GB2533454A (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
| EA201591541A1 (ru) | Ингибиторы бета-секретазы 1 (bace 1) | |
| MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
| GB201302704D0 (en) | Therapeutic compounds | |
| NZ702254A (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| MX2014013758A (es) | Derivados de tiazolcarboxamida para usarse como inhibidores de nampt. | |
| MX2017014752A (es) | Nuevos etinos de amidoheteroaril aroil hidrazida. | |
| PH12017501668A1 (en) | Bace1 inhibitors | |
| IN2015MN00045A (es) | ||
| MX2018007517A (es) | Compuestos triciclicos y composiciones como inhibidores de quinasa. | |
| MX2021015898A (es) | Compuestos heterocíclicos bicíclicos como inhibidores de actividad de ofbcdin3d. |